Clinical TrialJun 15, 2026, 08:47 AM
NewcelX Publishes Peer-Reviewed Study on Stem Cell Therapy
AI Summary
NewcelX Ltd. announced the publication of a peer-reviewed study in Stem Cell Reports, demonstrating the broad therapeutic potential of its stem cell technology platform. The study focused on AstroRx®, an hESC-derived astrocyte therapy, showing its ability to address key barriers to remyelination in multiple sclerosis (MS) and other chronic demyelinating diseases. This validates the company's platform for developing scalable cell therapies, while NewcelX continues to advance its lead candidate NCEL-101 for type 1 diabetes.
Key Highlights
- NewcelX published a peer-reviewed study on AstroRx® in Stem Cell Reports.
- AstroRx® is an hESC-derived astrocyte therapy for multiple sclerosis (MS) and other chronic demyelinating diseases.
- The study demonstrated AstroRx® enhances myelin debris clearance by microglia.
- It supports lymphocyte-mediated immune regulation and accelerates OPC differentiation.
- This validates NewcelX's stem cell technology platform for scalable therapeutic assets.
- The company continues to advance its lead candidate NCEL-101 for type 1 diabetes.
Price Impact
More from NCEL